Hydroxychloroquine
- Generic Name
- Hydroxychloroquine
- Brand Names
- Plaquenil, Sovuna
- Drug Type
- Small Molecule
- Chemical Formula
- C18H26ClN3O
- CAS Number
- 118-42-3
- Unique Ingredient Identifier
- 4QWG6N8QKH
- Background
Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like chloroquine. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxychloroquine is also used for the prophylaxi...
- Indication
Hydroxychloroquine is indicated for the prophylaxis of malaria where chloroquine resistance is not reported, treatment of uncomplicated malaria (caused by P. falciparum, P. malariae, P. ovale, or P. vivax), chronic discoid lupus erythematosus, systemic lupus erythematosus, acute rheumatoid arthritis, and chronic rheumatoid arthritis.
- Associated Conditions
- Acute Rheumatoid Arthritis, Malaria, Porphyria Cutanea Tarda, Q Fever, Sjogren's Syndrome (SS), Systemic Lupus Erythematosus, Uncomplicated Malaria caused by Plasmodium Vivax, Uncomplicated Malaria caused by Plasmodium malariae, Uncomplicated Malaria caused by Plasmodium ovale, Chronic Discoid Lupus Erythematosus (DLE), Chronic Rheumatoid Arthritis, Uncomplicated Malaria caused by Plasmodium falciparum
- Associated Therapies
- -
The (HD)IVACOV Trial (The High-Dose IVermectin Against COVID-19 Trial)
- Conditions
- Interventions
- First Posted Date
- 2021-01-15
- Last Posted Date
- 2021-01-15
- Lead Sponsor
- Corpometria Institute
- Target Recruit Count
- 294
- Registration Number
- NCT04712279
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Methotrexate vs Hydroxychloroquine
- First Posted Date
- 2020-12-31
- Last Posted Date
- 2021-11-23
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 133553
- Registration Number
- NCT04691505
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine as Treatment in Untreated Pancreas Cancer
- First Posted Date
- 2020-12-16
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- HonorHealth Research Institute
- Target Recruit Count
- 19
- Registration Number
- NCT04669197
- Locations
- 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
Efficacy and Safety of Ivermectin for Treatment and Prophylaxis of COVID-19 Pandemic
- Conditions
- Interventions
- First Posted Date
- 2020-12-16
- Last Posted Date
- 2020-12-16
- Lead Sponsor
- Benha University
- Target Recruit Count
- 600
- Registration Number
- NCT04668469
- Locations
- 🇪🇬
Benha Faculty of Medicine, Benha University, Banhā, Qaluopia, Egypt
Rapid Development and Implementation of a Remote ECG-monitored Prospective Randomized Clinical Trial During a Pandemic: Hydroxychloroquine Prophylaxis in COVID-19 Household Contacts
- Conditions
- Interventions
- First Posted Date
- 2020-12-03
- Last Posted Date
- 2020-12-03
- Lead Sponsor
- Bryn Mawr Hospital
- Target Recruit Count
- 54
- Registration Number
- NCT04652648
- Locations
- 🇺🇸
Lankenau Medical Center, Wynnewood, Pennsylvania, United States
🇺🇸Bryn Mawr Hospital, Bryn Mawr, Pennsylvania, United States
🇺🇸Paoli Hospital, Paoli, Pennsylvania, United States
A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19
- First Posted Date
- 2020-10-28
- Last Posted Date
- 2022-05-05
- Lead Sponsor
- Rutgers, The State University of New Jersey
- Target Recruit Count
- 7
- Registration Number
- NCT04605588
- Locations
- 🇺🇸
Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
Chemoprevention Clinical Trial of COVID-19: Hydroxychloroquine Post Exposure Prophylaxis
- First Posted Date
- 2020-10-22
- Last Posted Date
- 2020-10-22
- Target Recruit Count
- 93
- Registration Number
- NCT04597775
Safety and Efficacy of Hydroxychloroquine for the Treatment & Prevention of Coronavirus Disease 2019 (COVID-19) Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
- Conditions
- Interventions
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2021-12-07
- Lead Sponsor
- International Brain Research Foundation
- Registration Number
- NCT04590274
Treatment of Pregnancy RA
- Conditions
- Interventions
- First Posted Date
- 2020-09-30
- Last Posted Date
- 2020-10-01
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT04569890
- Locations
- 🇨🇳
Renji Hospital, Shanghai, Shanghai, China
Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).
- Conditions
- Interventions
- First Posted Date
- 2020-09-28
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 2
- Registration Number
- NCT04566133
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.